Table 1.
Parameter Estimates for the Plasma‐ELF PK Population Model for Ceftolozane and Tazobactam in Healthy Volunteers
| Parameters for Ceftolozane | Mean | SE | 95%CI |
|---|---|---|---|
| CL, L/h | 6.3 | 0.187 | 5.93–6.66 |
| Vc, L | 10.3 | 0.57 | 9.21–11.4 |
| Qce, L/h | 0.85 | 0.362 | 0.141–1.56 |
| Qec, L/h | 1.66 | 0.677 | 0.335–2.99 |
| Q2, L/h | 3.39 | 0.711 | 1.99–4.78 |
| V2, L | 3.76 | 0.392 | 2.99–4.53 |
| Variance of RVP | 0.00603 | 0.00238 | 0.00136–0.0107 |
| Variance of RVA | 0.297 | 0.139 | 0.0246–0.570 |
| Variance of IIV on CL | 0.0179 | 0.00529 | 0.00750–0.0282 |
| Variance of IIV on Vc | 0.0498 | 0.0174 | 0.0156–0.0840 |
| Variance of IIV on Qce | 0.174 | 0.0454 | 0.0849–0.263 |
| Parameters for Tazobactam | Mean | SE | 95%CI |
|---|---|---|---|
| CL, L/h | 24.5 | 0.578 | 23.4–25.6 |
| Vc, L, at 70‐kg body weight | 15.0 | 0.557 | 13.9–16.1 |
| Qce, L/h | 0.792 | 0.14 | 0.518–1.07 |
| Qec, L/h | 1.72 | 0.339 | 1.06–2.38 |
| Q2, L/h | 3.91 | 0.823 | 2.3–5.52 |
| V2, L | 4.42 | 0.483 | 3.47–5.37 |
| Exponent of (CrCL/119) on CL | 0.438 | 0.112 | 0.218–0.658 |
| Variance of IIV on CL | 0.00412 | 0.00228 | 0–0.00859 |
| Variance of IIV on Qec | 0.229 | 0.0689 | 0.094–0.364 |
| Variance of RVP | 0.0233 | 0.00404 | 0.0154–0.0312 |
CI, confidence interval; IIV, interindividual variability; RVA, additive residual variability; RVP, proportional residual variability; SE, standard error.